CN112574917A - 一株缓解高尿酸血症的鼠李糖乳杆菌ccfm1131 - Google Patents
一株缓解高尿酸血症的鼠李糖乳杆菌ccfm1131 Download PDFInfo
- Publication number
- CN112574917A CN112574917A CN202011488400.3A CN202011488400A CN112574917A CN 112574917 A CN112574917 A CN 112574917A CN 202011488400 A CN202011488400 A CN 202011488400A CN 112574917 A CN112574917 A CN 112574917A
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- ccfm1131
- hyperuricemia
- serum
- uric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 83
- 201000001431 Hyperuricemia Diseases 0.000 title claims abstract description 54
- 210000002966 serum Anatomy 0.000 claims abstract description 46
- 230000000694 effects Effects 0.000 claims abstract description 40
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 32
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 31
- 229940116269 uric acid Drugs 0.000 claims abstract description 31
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 22
- 102100033220 Xanthine oxidase Human genes 0.000 claims abstract description 20
- 108010093894 Xanthine oxidase Proteins 0.000 claims abstract description 20
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims abstract description 16
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 15
- 201000005569 Gout Diseases 0.000 claims abstract description 12
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims abstract description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 9
- 239000008103 glucose Substances 0.000 claims abstract description 8
- 244000005700 microbiome Species 0.000 claims abstract description 6
- 235000013305 food Nutrition 0.000 claims abstract description 5
- 210000004369 blood Anatomy 0.000 claims description 17
- 239000008280 blood Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 210000003405 ileum Anatomy 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 7
- 108020004999 messenger RNA Proteins 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000007884 disintegrant Substances 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 235000021107 fermented food Nutrition 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 7
- 235000012000 cholesterol Nutrition 0.000 abstract description 3
- 239000002068 microbial inoculum Substances 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 8
- 235000018291 probiotics Nutrition 0.000 description 8
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 7
- 229960003459 allopurinol Drugs 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000012258 culturing Methods 0.000 description 5
- 230000029142 excretion Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000003672 processing method Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 108020004465 16S ribosomal RNA Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- IAPCTXZQXAVYNG-UHFFFAOYSA-M Potassium 2,6-dihydroxytriazinecarboxylate Chemical compound [K+].[O-]C(=O)C1=NC(=O)NC(=O)N1 IAPCTXZQXAVYNG-UHFFFAOYSA-M 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- YTRQFSDWAXHJCC-UHFFFAOYSA-N chloroform;phenol Chemical compound ClC(Cl)Cl.OC1=CC=CC=C1 YTRQFSDWAXHJCC-UHFFFAOYSA-N 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- -1 Tris saturated phenol Chemical class 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 229950000193 oteracil Drugs 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000004144 purine metabolism Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010078530 urate transporter Proteins 0.000 description 1
- 230000003424 uricosuric effect Effects 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011488400.3A CN112574917B (zh) | 2020-12-16 | 2020-12-16 | 一株缓解高尿酸血症的鼠李糖乳杆菌ccfm1131 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011488400.3A CN112574917B (zh) | 2020-12-16 | 2020-12-16 | 一株缓解高尿酸血症的鼠李糖乳杆菌ccfm1131 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112574917A true CN112574917A (zh) | 2021-03-30 |
CN112574917B CN112574917B (zh) | 2022-08-09 |
Family
ID=75135541
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011488400.3A Active CN112574917B (zh) | 2020-12-16 | 2020-12-16 | 一株缓解高尿酸血症的鼠李糖乳杆菌ccfm1131 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112574917B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112481172A (zh) * | 2020-12-16 | 2021-03-12 | 江南大学 | 鼠李糖乳杆菌ccfm1130及其缓解治疗痛风的应用 |
CN113181377A (zh) * | 2021-04-30 | 2021-07-30 | 青岛大学 | Abcg2蛋白在制备改善、治疗或辅助治疗高尿酸血症伴高血脂、高血糖的制剂中的应用 |
CN114574382A (zh) * | 2022-01-17 | 2022-06-03 | 南京农业大学 | 具有预防或缓解高尿酸血症的鼠李糖乳杆菌fmb14及应用 |
CN116836889A (zh) * | 2023-08-14 | 2023-10-03 | 东北农业大学 | 一种缓解高尿酸的鼠李糖乳杆菌jl-1及其后生元和应用 |
CN117645946A (zh) * | 2023-11-09 | 2024-03-05 | 重庆第二师范学院 | 一种用于预防和干预关节炎的鼠李糖乳杆菌afy05及其应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2718157A1 (en) * | 2007-11-29 | 2009-06-04 | Meiji Dairies Corporation | Lactobacillus gasseri capable of lowering blood uric acid level |
CA2851018A1 (en) * | 2007-11-29 | 2009-06-04 | Hiroshi Tsuboi | Lactic acid bacteria having action of lowering blood uric acid level |
US20150250835A1 (en) * | 2014-03-07 | 2015-09-10 | Genmont Biotech Inc. | Composition and method of lactobacillus reuteri gmnl-89 in treating type 2 diabetes |
US20160051602A1 (en) * | 2014-08-22 | 2016-02-25 | Food Industry Research And Development Institute | Novel strain of lactobacillus rhamnosus and its metabolites for use in inhibiting xanthine oxidase and treating gout |
US20160082055A1 (en) * | 2013-04-09 | 2016-03-24 | Pierre Fabre Medicament | Composition comprising a combination of an elder extract and a strain of lactobacillus rhamnosus |
CN108486007A (zh) * | 2018-03-22 | 2018-09-04 | 嘉兴益诺康生物科技有限公司 | 一种用于降低血尿酸的干酪乳杆菌株、益生菌组合物及其应用 |
CN110305820A (zh) * | 2019-08-19 | 2019-10-08 | 江南大学 | 鼠李糖乳杆菌ccfm1064及其应用 |
WO2019203827A1 (en) * | 2018-04-19 | 2019-10-24 | Kibow Biotech Inc . | Composition and method for preventing or treating hyperuricemia or gout |
CN110638843A (zh) * | 2019-08-19 | 2020-01-03 | 江南大学 | 鼠李糖乳杆菌ccfm1060在制备功能性菌剂、食品和/或药物中的应用 |
CN111826315A (zh) * | 2020-07-20 | 2020-10-27 | 广东南芯医疗科技有限公司 | 一株鼠李糖乳杆菌nx-2及其在制备降尿酸药物中的应用 |
CN112263669A (zh) * | 2020-09-21 | 2021-01-26 | 康美华大基因技术有限公司 | 一种用于缓解高尿酸血症的低聚肽中药益生菌复合物 |
CN112458027A (zh) * | 2020-12-16 | 2021-03-09 | 江南大学 | 一株格氏乳杆菌及其缓解和治疗高尿酸血症的用途 |
-
2020
- 2020-12-16 CN CN202011488400.3A patent/CN112574917B/zh active Active
Patent Citations (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2718157A1 (en) * | 2007-11-29 | 2009-06-04 | Meiji Dairies Corporation | Lactobacillus gasseri capable of lowering blood uric acid level |
CA2851018A1 (en) * | 2007-11-29 | 2009-06-04 | Hiroshi Tsuboi | Lactic acid bacteria having action of lowering blood uric acid level |
US20160082055A1 (en) * | 2013-04-09 | 2016-03-24 | Pierre Fabre Medicament | Composition comprising a combination of an elder extract and a strain of lactobacillus rhamnosus |
US20150250835A1 (en) * | 2014-03-07 | 2015-09-10 | Genmont Biotech Inc. | Composition and method of lactobacillus reuteri gmnl-89 in treating type 2 diabetes |
US20160051602A1 (en) * | 2014-08-22 | 2016-02-25 | Food Industry Research And Development Institute | Novel strain of lactobacillus rhamnosus and its metabolites for use in inhibiting xanthine oxidase and treating gout |
CN105497078A (zh) * | 2014-08-22 | 2016-04-20 | 财团法人食品工业发展研究所 | 新颖的鼠李糖乳杆菌菌株及其用于抑制黄嘌呤氧化酶及治疗痛风的代谢产物 |
CN108486007A (zh) * | 2018-03-22 | 2018-09-04 | 嘉兴益诺康生物科技有限公司 | 一种用于降低血尿酸的干酪乳杆菌株、益生菌组合物及其应用 |
WO2019203827A1 (en) * | 2018-04-19 | 2019-10-24 | Kibow Biotech Inc . | Composition and method for preventing or treating hyperuricemia or gout |
CN110305820A (zh) * | 2019-08-19 | 2019-10-08 | 江南大学 | 鼠李糖乳杆菌ccfm1064及其应用 |
CN110638843A (zh) * | 2019-08-19 | 2020-01-03 | 江南大学 | 鼠李糖乳杆菌ccfm1060在制备功能性菌剂、食品和/或药物中的应用 |
CN111826315A (zh) * | 2020-07-20 | 2020-10-27 | 广东南芯医疗科技有限公司 | 一株鼠李糖乳杆菌nx-2及其在制备降尿酸药物中的应用 |
CN112263669A (zh) * | 2020-09-21 | 2021-01-26 | 康美华大基因技术有限公司 | 一种用于缓解高尿酸血症的低聚肽中药益生菌复合物 |
CN112458027A (zh) * | 2020-12-16 | 2021-03-09 | 江南大学 | 一株格氏乳杆菌及其缓解和治疗高尿酸血症的用途 |
Non-Patent Citations (7)
Title |
---|
CAIXIN NI等: "Lactic acid bacteria strains relieve hyperuricaemia by suppressing xanthine oxidase activity via a short-chain fatty acid-dependent mechanism", 《FOOD & FUNCTION》 * |
F. CHEN等: "Effects of dietary Lactobacillus rhamnosus CF supplementation on growth, meat quality, and microenvironment in specific pathogen-free chickens", 《POULTRY SCIENCE》 * |
HONG-SUP YOON等: "The probiotic Lactobacillus rhamnosus BFE5264 and Lactobacillus plantarum NR74 promote cholesterol efflux and suppress inflammation in THP-1 cells", 《JOURNAL OF THE SCIENCE OF FOOD AND AGRICULTURE》 * |
倪彩新: "乳杆菌对高尿酸血症的影响及作用途径探究", 《中国优秀硕士学位论文全文数据库(电子期刊)工程科技Ⅰ辑》 * |
彭新颜等: "乳酸菌抗氧化作用研究进展", 《食品科学》 * |
方志锋等: "益生菌对高血压影响的研究进展", 《食品科学》 * |
樊代明: "《整合医学 理论与实践 6》", 30 April 2019, 上海:上海世界图书出版公司 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112481172A (zh) * | 2020-12-16 | 2021-03-12 | 江南大学 | 鼠李糖乳杆菌ccfm1130及其缓解治疗痛风的应用 |
CN112481172B (zh) * | 2020-12-16 | 2022-07-05 | 江南大学 | 鼠李糖乳杆菌ccfm1130及其缓解治疗痛风的应用 |
CN113181377A (zh) * | 2021-04-30 | 2021-07-30 | 青岛大学 | Abcg2蛋白在制备改善、治疗或辅助治疗高尿酸血症伴高血脂、高血糖的制剂中的应用 |
CN114574382A (zh) * | 2022-01-17 | 2022-06-03 | 南京农业大学 | 具有预防或缓解高尿酸血症的鼠李糖乳杆菌fmb14及应用 |
CN114574382B (zh) * | 2022-01-17 | 2023-06-27 | 南京农业大学 | 具有预防或缓解高尿酸血症的鼠李糖乳杆菌fmb14及应用 |
CN116836889A (zh) * | 2023-08-14 | 2023-10-03 | 东北农业大学 | 一种缓解高尿酸的鼠李糖乳杆菌jl-1及其后生元和应用 |
CN116836889B (zh) * | 2023-08-14 | 2023-11-17 | 东北农业大学 | 一种缓解高尿酸的鼠李糖乳杆菌jl-1及其后生元和应用 |
CN117645946A (zh) * | 2023-11-09 | 2024-03-05 | 重庆第二师范学院 | 一种用于预防和干预关节炎的鼠李糖乳杆菌afy05及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112574917B (zh) | 2022-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112458027B (zh) | 一株格氏乳杆菌及其缓解和治疗高尿酸血症的用途 | |
CN112574917B (zh) | 一株缓解高尿酸血症的鼠李糖乳杆菌ccfm1131 | |
CN114196581B (zh) | 缓解高尿酸血症的罗伊氏乳杆菌ccfm1132及应用 | |
CN112813003B (zh) | 一株植物乳杆菌及其在制备缓解高血脂症引发的疾病的药物或食品中的应用 | |
CN114350577B (zh) | 一种改善便秘的动物双歧杆菌乳亚种BLa36及其培养方法与应用 | |
CN114181864B (zh) | 一种鼠李糖乳杆菌hf01及其应用 | |
CN114107088B (zh) | 一种罗伊氏乳杆菌lrsy523及其应用 | |
CN109628346B (zh) | 发酵乳杆菌cqpc04及其在制备发酵食品中的应用 | |
CN110093287B (zh) | 假小链双歧杆菌ccfm1045、其组合物、发酵食品、用途、菌剂及其菌剂制备方法 | |
CN113025526B (zh) | 一株减少结肠病理损伤且具有缓解便秘作用的两歧双歧杆菌 | |
CN110106103B (zh) | 假小链双歧杆菌ccfm1047、其组合物、发酵食品、用途、菌剂及其菌剂制备方法 | |
CN109593678B (zh) | 长双歧杆菌yh295及其在制备降低腹型肥胖风险产品中的应用 | |
WO2021143621A1 (zh) | Anaerostipes sp B2131菌及其在炎症性肠病中的应用 | |
CN113797232B (zh) | 具有缓解胰岛素抵抗功能的组合物及其应用 | |
CN116769658A (zh) | 一种凝结芽孢杆菌ap15及其在肠道调节与尿酸、胆固醇代谢的应用 | |
CN113717883B (zh) | 促进机体健康长寿的植物乳杆菌flpl05及其应用 | |
CN114854638A (zh) | 一株高效表达腺苷脱氨酶缓解结肠炎副干酪乳杆菌 | |
CN113151070B (zh) | 一株可提高肠道中克里斯藤森菌科相对丰度的发酵乳杆菌 | |
CN110331118B (zh) | 青春双歧杆菌ccfm1061、其发酵食品及菌剂制备方法 | |
CN113249256B (zh) | 一株缓解雌激素相关代谢紊乱及肥胖的植物乳杆菌及应用 | |
CN112481172B (zh) | 鼠李糖乳杆菌ccfm1130及其缓解治疗痛风的应用 | |
CN114410531A (zh) | 降低血浆tmao及缓解、预防动脉粥样硬化的长双歧杆菌ccfm1216及其应用 | |
CN114410532A (zh) | 一株降低血浆氧化三甲胺和盲肠三甲胺水平的长双歧杆菌及其应用 | |
CN112236155A (zh) | 一种组合物及其应用 | |
CN117866834A (zh) | 一株缓解高尿酸血症的发酵乳杆菌M5e及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220124 Address after: 214000 room 602, No.5, beichansi lane, Chong'an District, Wuxi City, Jiangsu Province Applicant after: Zhao Jianxin Address before: 214000 1800 Lihu Avenue, Binhu District, Wuxi, Jiangsu Applicant before: Jiangnan University |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20220323 Address after: 214000 first floor, 35-102, Changjiang South Road, Xinwu District, Wuxi City, Jiangsu Province Applicant after: Wuxi special food and Nutrition Health Research Institute Co.,Ltd. Address before: 214000 room 602, No.5, beichansi lane, Chong'an District, Wuxi City, Jiangsu Province Applicant before: Zhao Jianxin |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210330 Assignee: Shanghai Huapu Life Health Technology Co.,Ltd. Assignor: Wuxi special food and Nutrition Health Research Institute Co.,Ltd. Contract record no.: X2024980005362 Denomination of invention: A strain of Lactobacillus rhamnosus CCFM1131 that alleviates hyperuricemia Granted publication date: 20220809 License type: Common License Record date: 20240508 |